Skip to main content

Table 4 Comparisons of demographics and baseline clinical characteristics of the patients in the derivation and validation cohort

From: A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study

Variables Validation cohort(n = 156) derivation cohort (n = 421) P value
Age (years) 48.92 ± 11.94 47.93 ± 11.40 0.372
Gender (M: F) 129/27 365/56
Cirrhosis (%) 114(73.1%) 299(71.02%) 0.627
Bacterial infections 101(64.74%) 307(72.92%) 0.055
TBIL (μmol/L) 239.43 ± 136.17 323.39 ± 165.69 < 0.001
INR 1.92(1.58, 2.43) 2.25(1.86, 2.76) < 0.001
Cr (μmol/L) 62.40(52.15, 80.35) 69.30(57.28, 87.90) 0.004
RDW (%) 16.10(14.50, 18.10) 15.90(14.38, 18.42) 0.842
MPV (FL) 11.29 ± 1.67 11.74 ± 1.53 0.003
NLR 4.33(2.68, 7.87) 4.84(3.19, 8.07) < 0.001
MLR 0.61(0.41, 0.90) 0.64(0.42, 0.94) 0.473
GPR 0.91(0.53, 1.50) 0.97(0.59, 1.69) 0.162
RPR 0.17(0.11, 0.28) 0.19(0.12, 0.30) 0.093
MPR 0.70(0.59, 0.83) 0.14(0.09, 0.20) < 0.001
PNI 35.03(30.65, 41.10) 34.10(30.20, 38.31) 0.033
PLR 95.92(63.99, 143.22) 91.03(62.69, 127.69) 0.206
RLR 17.77(11.73, 26.73) 16.70(3.71, 85.81) 0.939
MELD SCORE 21.41 ± 7.84 25.05 ± 6.75 < 0.001
MELD-Na 21.24 ± 15.66 24.32 ± 12.69 0.001
CTP 10.48 ± 1.89 11.09 ± 2.00 0.029
  1. TBIL total bilirubin, ALB albumin, γ-GGT gamma-glutamyl transpeptidase, Cr creatinine, Cyst-c Cystatin c, Serum Na + serum sodium, PT prothrombin time, INR international normalized ratio, PTA prothrombin activity, WBC white blood cell count, RDW red blood cell distribution width, NLR neutrophil/lymphocyte ratio, MLR monocyte/lymphocyte ratio, PLR platelet/lymphocyte ratio, RPR RDW/platelet ratio, GPR gamma-glutamyl transpeptidase/platelet ratio, MPV mean platelet volume, RLR RDW/lymphocyte ratio, PNI prognostic nutritional index, MPR MPV/platelet ratio, MELD model for end-stage liver disease, MELD-Na MELD-sodium score, CTP child-Turcotte Pugh score